Stargardt Disease

4
Pipeline Programs
1
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Alkeus Pharmaceuticals
4 programs
1
2
1
ALK-001Phase 31 trial
ALK-001Phase 21 trial
ALK-001Phase 21 trial
ALK-001Phase 11 trial
Active Trials
NCT02230228CompletedEst. Feb 2015
NCT04239625Active Not RecruitingEst. Dec 2026
NCT02402660Enrolling By InvitationEst. Nov 2026
+1 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Alkeus PharmaceuticalsALK-001
Alkeus PharmaceuticalsALK-001
Alkeus PharmaceuticalsALK-001
Alkeus PharmaceuticalsALK-001

Clinical Trials (4)

NCT07419334Alkeus PharmaceuticalsALK-001

Study of ALK-001 on the Progression of Stargardt Disease

Start: Mar 2026Est. completion: Dec 2030
Phase 3Not Yet Recruiting
NCT04239625Alkeus PharmaceuticalsALK-001

Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)

Start: Dec 2019Est. completion: Dec 2026
Phase 2Active Not Recruiting
NCT02402660Alkeus PharmaceuticalsALK-001

Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

Start: Aug 2015Est. completion: Nov 2026
Phase 2Enrolling By Invitation
NCT02230228Alkeus PharmaceuticalsALK-001

Phase 1 Safety Study of ALK-001 in Healthy Volunteers

Start: Apr 2014Est. completion: Feb 2015
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space